From the Division of Thoracic Surgery, Department of Health, Taichung Hospital, Executive Yuan, Taichung, Taiwan.
Central Taiwan University of Science and Technology, Taichung, Taiwan.
Anesth Analg. 2024 May 1;138(5):1107-1119. doi: 10.1213/ANE.0000000000006595. Epub 2023 Jun 30.
Paclitaxel (PTX), which is a first-line chemotherapy drug used to treat various types of cancers, exhibits peripheral neuropathy as a common side effect that is difficult to treat. Protein arginine methyltransferase 5 (PRMT 5) is a key regulator of the chemotherapy response, as chemotherapy drugs induce PRMT5 expression. However, little is known about the PRMT5-mediated epigenetic mechanisms involved in PTX-induced neuropathic allodynia.
Sprague-Dawley rats were intraperitoneally given PTX to induce neuropathic pain. Biochemical analyses were conducted to measure the protein expression levels in the dorsal root ganglion (DRG) of the animals. The von Frey test and hot plate test were used to evaluate nociceptive behaviors.
PTX increased the PRMT5 (mean difference [MD]: 0.68, 95% confidence interval [CI], 0.88-0.48; P < .001 for vehicle)-mediated deposition of histone H3R2 dimethyl symmetric (H3R2me2s) at the transient receptor potential vanilloid 1 ( Trpv1 ) promoter in the DRG. PRMT5-induced H3R2me2s recruited WD repeat domain 5 (WDR5) to increase trimethylation of lysine 4 on histone H3 (H3K4me3) at Trpv1 promoters, thus resulting in TRPV1 transcriptional activation (MD: 0.65, 95% CI, 0.82-0.49; P < .001 for vehicle) in DRG in PTX-induced neuropathic pain. Moreover, PTX increased the activity of NADPH oxidase 4 (NOX4) (MD: 0.66, 95% CI, 0.81-0.51; P < .001 for vehicle), PRMT5-induced H3R2me2s, and WDR5-mediated H3K4me3 in the DRG in PTX-induced neuropathic pain. Pharmacological antagonism and the selective knockdown of PRMT5 in DRG neurons completely blocked PRMT5-mediated H3R2me2s, WDR5-mediated H3K4me3, or TRPV1 expression and neuropathic pain development after PTX injection. Remarkably, NOX4 inhibition not only attenuated allodynia behavior and reversed the above-mentioned signaling but also reversed NOX4 upregulation via PTX.
Thus, the NOX4/PRMT5-associated epigenetic mechanism in DRG has a dominant function in the transcriptional activation of TRPV1 in PTX-induced neuropathic pain.
紫杉醇(PTX)是一种用于治疗多种癌症的一线化疗药物,其常见的副作用是外周神经病变,这种病变难以治疗。精氨酸甲基转移酶 5(PRMT5)是化疗反应的关键调节剂,因为化疗药物诱导 PRMT5 表达。然而,PRMT5 介导的表观遗传机制在 PTX 诱导的神经性痛觉过敏中的作用知之甚少。
向 Sprague-Dawley 大鼠腹腔内给予 PTX 以诱导神经性疼痛。进行生化分析以测量动物背根神经节(DRG)中的蛋白质表达水平。使用 Von Frey 测试和热板测试评估伤害感受行为。
PTX 增加了 DRG 中转录因子香草素受体 1(Trpv1)启动子处 PRMT5(中位数差异 [MD]:0.68,95%置信区间 [CI],0.88-0.48;PTX 组与载体组相比,P <.001)介导的组蛋白 H3R2 二甲基对称(H3R2me2s)沉积。PRMT5 诱导的 H3R2me2s 募集 WD 重复结构域 5(WDR5)以增加组蛋白 H3 赖氨酸 4 上的三甲基化(H3K4me3)在 Trpv1 启动子处,从而导致 TRPV1 转录激活(MD:0.65,95%CI,0.82-0.49;PTX 组与载体组相比,P <.001)在 DRG 中 PTX 诱导的神经性疼痛。此外,PTX 增加了烟酰胺腺嘌呤二核苷酸磷酸氧化酶 4(NOX4)(MD:0.66,95%CI,0.81-0.51;PTX 组与载体组相比,P <.001)、PRMT5 诱导的 H3R2me2s 和 WDR5 介导的 H3K4me3 在 DRG 中 PTX 诱导的神经性疼痛。DRG 神经元中的药理学拮抗和 PRMT5 的选择性敲低完全阻断了 PRMT5 介导的 H3R2me2s、WDR5 介导的 H3K4me3 或 TRPV1 表达以及 PTX 注射后神经性疼痛的发展。值得注意的是,NOX4 抑制不仅减轻了痛觉过敏行为,还逆转了上述信号转导,并且通过 PTX 逆转了 NOX4 的上调。
因此,DRG 中的 NOX4/PRMT5 相关表观遗传机制在 PTX 诱导的神经性痛觉过敏中的 TRPV1 转录激活中具有主导作用。